Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis

NCT04195906 is registered in ClinicalTrials.gov with Sanifit Therapeutics S. A. as lead sponsor.

NCT NCT04195906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04195906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis
Lead sponsor
Sanifit Therapeutics S. A.
Phase
Phase 3
Overall status
Completed
Start date
February 12, 2020
Completion date
October 24, 2022
Enrollment
71 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

calcific uremic arteriolopathy, calciphylaxis